About
Dr. Antonius Schuh has been the chief executive for a series of successful start-up molecular diagnostic companies. Currently he is the chief executive officer of Trovagene, a company specializing in the detection and analysis of transrenal nucleic acids in urine. Prior to Trovagene, Dr. Schuh served as chairman and chief executive officer of Sorrento Therapeutics, Inc., a biotechnology company he co-founded based on a proprietary platform to generate fully human mAb libraries. Previously, he was the founding CEO of AviaraDx, Inc., a leading molecular diagnostic innovator in oncology, where he led its sale to bioMérieux. Before AviaraDx, he served as CEO of Arcturus Bioscience, Inc., where he led the sale of Arcturus’ life science business to Molecular Devices, Inc., now part of MDS. Prior to Arcturus, Dr. Schuh served as the president and chief executive officer of Sequenom, Inc. He joined Sequenom as managing director of the company’s German operations, Sequenom GmbH, from Helm
Position in the VCSift Database
- • 2 investors at SelectION are tracked.
- • 3,360 investors hold the CEO role in VCSift. Antonius Schuh is one of them.
- • 829 investors are based in San Diego, California, United States.
Data sourced from 410,343 investor profiles. Updated July 2026.
Investment Focus
- Location
- San Diego, US
Contact Information
Find more investors like Antonius
Search Investors